You are here : Home > Research Centers and Units > Infectious desease models of innovative therapies - IDMIT

Infectious desease models of innovative therapies - IDMIT

Published on 9 February 2017
IDMIT is a national infrastructure funded in 2012 by the national “programme d’investissements d’avenirs” (PIA). The Life Sciences Division of the CEA, the “Institut Pasteur”, the “Institut National de la Santé et de la Recherche Médicale” (Inserm), the “Agence Nationale de Recherche sur le SIDA et les Hépatites Virales” (ANRS), the Paris Sud 11 University (UPS-11), and BertinPharma, a CRO specialized on bioassays development and preclinical and clinical studies, have joined their forces to create a preclinical and technological research infrastructure focused on human infectious diseases, vaccines and innovative therapies. ​There is no equivalent infrastructure in Europe which combines the complementary expertise of the partners, all international leaders in the field, with the outstanding core facilities implemented in IDMIT for monitoring diseases and treatments including advanced technologies for high dimensional cell phenotyping (CyTof) and in vivo imaging (Near Infra Red fluorescence, two-photon microscope, confocal-endo microscopy, PET-CT). 

The major objective of IDMIT is to provide the national and international scientific community with a highly competitive infrastructure for preclinical research, facilitating the discovery of markers of safety and efficacy of new vaccines and treatments and accelerating the translation of innovations from the bench to clinical practice. ​


The aims of IDMIT are:
  • ​To better understand the complexity of host/pathogen interactions, with the objective to deeply characterize animal models, including NHP, of human infectious diseases so that guaranteeing their relevance and limits for the scientific objective of our collaborators and partners.
  • To provide the appropriate environment for assurance quality and an organization compatible with legal and time lines constrains of our partners engaged in drug development.
  • To develop new technologies and high dimensional phenotyping and in vivo imaging in particular, for study infectious diseases and development of drugs and vaccines.

​Of particular interest is the implementation of innovative equipment and technologies for the in vivo imaging (fluorescence, PET-CT) of infected animals in BSL2 and BSL3 containment conditions.
IDMIT also fosters research programs for refining and reduced the use of animals required for experimental medicine. Programs on assays standardization and harmonization, non-invasive methods and in silico modelling are developed. A reagents repository and a Centre of Biological Resources (CBR) have been created.